Cas no for 461432-26-8,(2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol ACID Cas number search msds database,online free cas number chemistry search engine,cas number sigma aldrich

Post Sourcing Request Exhibition

Home > CAS No. Inquiry > 461432-26-8

[CAS Name] (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

[Formula] C21H25ClO6

Search Products Post Sourcing Request

[CAS Name](2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
[Alias]Dapagliflozin; BMS-512148; (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol
[Number]461432-26-8
[EINECS]
[Formula]C21H25ClO6
[Molecular weight]408.8726

461432-26-8 Suppliers

Company

Main Products

Shenzhen Haorui Pharmatech Co., Ltd.	Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.	Send Inquiry
Sichuan Gowell Pharmaceutical Co.,Ltd.	Uses: Treat diabetes, lower blood sugar	Send Inquiry

Previous page 1 2 3 4 5 6 7 8 9 Next page

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us: About PharmaSources; Terms of Service; Privacy Policy; Intellectual Property; Media Partners

PharmaSources Customer Service